{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:48:17Z","timestamp":1782143297342,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-026-05055-9","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:18:20Z","timestamp":1770794300000},"page":"9513-9525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase\u2013driven non-small cell lung cancer therapy"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5196-8081","authenticated-orcid":false,"given":"Lohitha","family":"Gumma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargavi","family":"Gumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Prasanna","family":"Yarrabothula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"3","key":"5055_CR1","doi-asserted-by":"publisher","first-page":"e105784","DOI":"10.15252\/embj.2020105784","volume":"40","author":"M Boren\u00e4s","year":"2021","unstructured":"Boren\u00e4s M, Umapathy G, Lai WY, Lind DE, Witek B, Guan J, Mendoza-Garcia P, Masudi T, Claeys A, Chuang TP, El Wakil A, Arefin B, Fransson S, Koster J, Johansson M, Gaarder J, den Van Eyn J, Hallberg B, Palmer RH (2021) ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation. EMBO J 40(3):e105784. https:\/\/doi.org\/10.15252\/embj.2020105784","journal-title":"EMBO J"},{"issue":"3","key":"5055_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"5055_CR3","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","volume":"14","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, M\u00fcller B, Shaw AT (2019) Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib\u00a0in\u00a0untreated ALK-positive advanced non-small cell\u00a0lung cancer in the global phase III ALEX study. J Thorac Oncol 14(7):1233\u20131243. https:\/\/doi.org\/10.1016\/j.jtho.2019.03.007","journal-title":"J Thorac Oncol"},{"issue":"12","key":"5055_CR4","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Popat S (2021) Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol 16(12):2091\u20132108. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.035","journal-title":"J Thorac Oncol"},{"key":"5055_CR5","doi-asserted-by":"publisher","unstructured":"Camidge DR, Kim HR, Ahn M, Yang JC, Han J, Lee J, Hochmair MJ, Li JY, Chang G, Lee KH, Gridelli C, Delmonte A, Campelo RG, Kim D, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, . . . Popat S (2018) Brigatinib versus crizotinib in ALK -positive non\u2013small-cell lung cancer. N Engl J Med 379(21): 2027\u20132039. https:\/\/doi.org\/10.1056\/nejmoa1810171","DOI":"10.1056\/nejmoa1810171"},{"issue":"7511","key":"5055_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543\u2013550. https:\/\/doi.org\/10.1038\/nature13385","journal-title":"Nature"},{"issue":"50","key":"5055_CR7","doi-asserted-by":"publisher","first-page":"82943","DOI":"10.18632\/oncotarget.12705","volume":"7","author":"S Dacic","year":"2016","unstructured":"Dacic S, Villaruz LC, Abberbock S, Mahaffey A, Incharoen P, Nikiforova MN (2016) ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget 7(50):82943\u201382952. https:\/\/doi.org\/10.18632\/oncotarget.12705","journal-title":"Oncotarget"},{"issue":"2","key":"5055_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"5055_CR9","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.21037\/tlcr-2019-cnsclc-09","volume":"9","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack I, Ritterhouse LL (2020) The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. Transl Lung Cancer Res 9(6):2557\u20132570. https:\/\/doi.org\/10.21037\/tlcr-2019-cnsclc-09","journal-title":"Transl Lung Cancer Res"},{"key":"5055_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00160","volume":"2018","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Gainor JF (2018) Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA. JCO Precis Oncol 2018:10.1200\/PO.17.00160. https:\/\/doi.org\/10.1200\/PO.17.00160","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"5055_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/105294199277860","volume":"6","author":"JR Dixon","year":"1998","unstructured":"Dixon JR (1998) The International Conference on Harmonization Good Clinical Practice guideline. Quality Assurance (San Diego, Calif) 6(2):65\u201374. https:\/\/doi.org\/10.1080\/105294199277860","journal-title":"Quality Assurance (San Diego, Calif)"},{"issue":"12","key":"5055_CR12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jtho.2021.07.008","volume":"16","author":"R Dziadziuszko","year":"2021","unstructured":"Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, P\u00e9rol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Gadgeel SM (2021) Blood First Assay Screening Trial (BFAST) in treatment-naive advanced or metastatic NSCLC: initial results of the phase 2 ALK-positive cohort. J Thorac Oncol 16(12):2040\u20132050. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.008","journal-title":"J Thorac Oncol"},{"issue":"2","key":"5055_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"5055_CR14","doi-asserted-by":"publisher","unstructured":"Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D\u2019Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, ... Hughes M (2019) NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Nat Compr Cancer Netw\u202f: JNCCN 17(12):1464\u20131472. https:\/\/doi.org\/10.6004\/jnccn.2019.0059","DOI":"10.6004\/jnccn.2019.0059"},{"key":"5055_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0675-9","volume":"20","author":"A Friedlaender","year":"2019","unstructured":"Friedlaender A, Banna G, Patel S et al (2019) Diagnosis and treatment of ALK aberrations in metastatic NSCLC. Curr Treat Options Oncol 20:79. https:\/\/doi.org\/10.1007\/s11864-019-0675-9","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"5055_CR16","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","volume":"29","author":"S Gadgeel","year":"2018","unstructured":"Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, P\u00e9rol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, N\u00fcesch E, Balas B, Camidge DR (2018) Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol 29(11):2214\u20132222. https:\/\/doi.org\/10.1093\/annonc\/mdy405","journal-title":"Ann Oncol"},{"issue":"7","key":"5055_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","volume":"18","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Shaw AT (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18(7):865\u2013875. https:\/\/doi.org\/10.1634\/theoncologist.2013-0095","journal-title":"Oncologist"},{"issue":"10","key":"5055_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6(10):1118\u20131133. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0596","journal-title":"Cancer Discov"},{"key":"5055_CR19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.09811","volume":"4","author":"J Guan","year":"2015","unstructured":"Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH (2015) FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. Elife 4:e09811. https:\/\/doi.org\/10.7554\/eLife.09811","journal-title":"Elife"},{"issue":"10089","key":"5055_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390(10089):29\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(17)30565-2","journal-title":"Lancet"},{"issue":"10","key":"5055_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.136","volume":"19","author":"L Hill","year":"2024","unstructured":"Hill L, Reddy P, Mertins B, Sanchez E, Selvaggi G, Bulow C (2024) MA06.09 predictors of long-term ensartinib response from the eXalt3 trial. J Thorac Oncol 19(10):S76. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.136","journal-title":"J Thorac Oncol"},{"issue":"12","key":"5055_CR22","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1158\/1078-0432.CCR-17-2398","volume":"24","author":"L Horn","year":"2018","unstructured":"Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA (2018a) Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I\/II, multicenter study. Clin Cancer Res 24(12):2771\u20132779. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2398","journal-title":"Clin Cancer Res"},{"key":"5055_CR23","doi-asserted-by":"publisher","first-page":"viii543","DOI":"10.1093\/annonc\/mdy292.121","volume":"29","author":"L Horn","year":"2018","unstructured":"Horn L, Wu YL, Reck M et al (2018b) eXalt3: phase III randomized study comparing ensartinib to crizotinib in ALKpositive NSCLC patients. Annals of Oncology 29:viii543","journal-title":"Annals of Oncology"},{"issue":"11","key":"5055_CR24","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","volume":"7","author":"L Horn","year":"2021","unstructured":"Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao Li, Selvaggi G, Wu YL (2021) Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol 7(11):1617\u20131625. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3523","journal-title":"JAMA Oncol"},{"issue":"11","key":"5055_CR25","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","volume":"14","author":"L Horn","year":"2019","unstructured":"Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lovly CM (2019) Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. J Thorac Oncol 14(11):1901\u20131911. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.003","journal-title":"J Thorac Oncol"},{"key":"5055_CR26","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218171s000lbl.pdf"},{"issue":"120","key":"5055_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003316","volume":"4","author":"R Katayama","year":"2012","unstructured":"Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4(120):120ra17. https:\/\/doi.org\/10.1126\/scitranslmed.3003316","journal-title":"Sci Transl Med"},{"issue":"10","key":"5055_CR28","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1158\/1078-0432.CCR-14-2791","volume":"21","author":"R Katayama","year":"2015","unstructured":"Katayama R, Lovly CM, Shaw AT (2015) Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 21(10):2227\u20132235. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2791","journal-title":"Clin Cancer Res"},{"issue":"22","key":"5055_CR29","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodr\u00edguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR (2017) Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology 35(22):2490\u20132498. https:\/\/doi.org\/10.1200\/JCO.2016.71.5904","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"5055_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.critrevonc.2013.09.003","volume":"89","author":"C Lazzari","year":"2014","unstructured":"Lazzari C, Spitaleri G, Catania C, Barberis M, Noberasco C, Santarpia M, Delmonte A, Toffalorio F, Conforti F, De Pas TM (2014) Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options. Crit Rev Oncol Hematol 89(3):358\u2013365. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.09.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"5055_CR31","doi-asserted-by":"publisher","unstructured":"Lin JJ, Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo-Jack, I., Jessop, N. A., Jiang, G. Y., Le, L. P., Gowen, K., Stephens, P. J., Ross, J. S., Ali, S. M., Miller, V. A., Johnson, M. L., Lovly, C. M., Hata, A. N., Gainor, J. F., Iafrate, A. J., Shaw, A. T., \u2026 Ou, S. I. (2018) Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol 36(12):1199\u20131206. https:\/\/doi.org\/10.1200\/JCO.2017.76.2294","DOI":"10.1200\/JCO.2017.76.2294"},{"issue":"3","key":"5055_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Yatabe Y (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 142(3):321\u2013346. https:\/\/doi.org\/10.5858\/arpa.2017-0388-CP","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"5055_CR33","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.21037\/jtd-22-1606","volume":"14","author":"Y Ma","year":"2022","unstructured":"Ma Y, Pan H, Liu Y, Zhang Y, Hong S, Huang J, Weng S, Yang Y, Fang W, Huang Y, Xiao S, Wang T, Ding L, Cui L, Zhang L, Zhao H (2022) Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial. J Thorac Dis 14(12):4751\u20134762. https:\/\/doi.org\/10.21037\/jtd-22-1606","journal-title":"J Thorac Dis"},{"issue":"14","key":"5055_CR34","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","volume":"24","author":"CE McCoach","year":"2018","unstructured":"McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC (2018) Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clin Cancer Res 24(14):3334\u20133347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2452","journal-title":"Clin Cancer Res"},{"issue":"12","key":"5055_CR35","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1158\/1078-0432.CCR-17-2588","volume":"24","author":"CE McCoach","year":"2018","unstructured":"McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC (2018) Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res 24(12):2758\u20132770. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2588","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"5055_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000524","volume":"4","author":"MG McCusker","year":"2019","unstructured":"McCusker MG, Russo A, Scilla KA, Mehra R, Rolfo C (2019) How I treat ALK-positive non-small cell lung cancer. ESMO Open 4(Suppl 2):e000524. https:\/\/doi.org\/10.1136\/esmoopen-2019-000524","journal-title":"ESMO Open"},{"issue":"4","key":"5055_CR37","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2214\/AJR.19.21982","volume":"214","author":"DP Mendoza","year":"2020","unstructured":"Mendoza DP, Lin JJ, Rooney MM, Chen T, Sequist LV, Shaw AT, Digumarthy SR (2020) Imaging features and metastatic patterns of advanced ALK-rearranged non-small cell lung cancer. AJR Am J Roentgenol 214(4):766\u2013774. https:\/\/doi.org\/10.2214\/AJR.19.21982","journal-title":"AJR Am J Roentgenol"},{"key":"5055_CR38","doi-asserted-by":"publisher","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S, ESMO Guidelines Committee (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 29(Suppl 4):iv192\u2013iv237. https:\/\/doi.org\/10.1093\/annonc\/mdy275","DOI":"10.1093\/annonc\/mdy275"},{"key":"5055_CR39","doi-asserted-by":"publisher","unstructured":"Mezquita L, Swalduz A, Jovelet C, Ortiz-Cuaran S, Howarth K, Planchard D, Avrillon V, Recondo G, Marteau S, Benitez JC, De Kievit F, Plagnol V, Lacroix L, Odier L, Rouleau E, Fournel P, Caramella C, Tissot C, Adam J, Woodhouse S, \u2026 Saintigny P (2020).Clinical relevance of an amplicon-based liquid biopsy for detecting ALK and ROS1 fusion and resistance mutations in patients with non-small-cell lung cancer. JCO Precis Oncol 4:PO.19.00281. https:\/\/doi.org\/10.1200\/PO.19.00281","DOI":"10.1200\/PO.19.00281"},{"issue":"8","key":"5055_CR40","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, P\u00e9rol M, Ou SI, Ahn JS, Shaw AT, Bordogna W, Smoljanovi\u0107 V, Hilton M, Ruf T, No\u00e9 J, Peters S (2020) Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals of Oncology\u202f: Official Journal of the European Society for Medical Oncology 31(8):1056\u20131064. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.478","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"issue":"5151","key":"5055_CR41","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science 263(5151):1281\u20131284. https:\/\/doi.org\/10.1126\/science.8122112","journal-title":"Science"},{"key":"5055_CR42","unstructured":"National Cancer Institute. Common terminology criteria for adverse events: version 4.03. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_4.03.xlsx. Accessed 29 July 2021"},{"issue":"6","key":"5055_CR43","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazi\u00e8res J, Oh IJ, de Castro J, Migliorino MR, Helland \u00c5, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J (2018) Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Annals of Oncology\u202f: Official Journal of the European Society for Medical Oncology 29(6):1409\u20131416. https:\/\/doi.org\/10.1093\/annonc\/mdy121","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"issue":"7","key":"5055_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/jco.2015.63.9443","volume":"34","author":"SH Ou","year":"2016","unstructured":"Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34(7):661\u2013668. https:\/\/doi.org\/10.1200\/jco.2015.63.9443","journal-title":"J Clin Oncol"},{"issue":"2","key":"5055_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12(2):175\u2013180","journal-title":"Lancet Oncol"},{"issue":"3","key":"5055_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1634\/theoncologist.2014-0389","volume":"20","author":"M Pekar-Zlotin","year":"2015","unstructured":"Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA Jr, Peled N (2015) Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 20(3):316\u2013322. https:\/\/doi.org\/10.1634\/theoncologist.2014-0389","journal-title":"Oncologist"},{"key":"5055_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00356","volume":"3","author":"NA Pennell","year":"2019","unstructured":"Pennell NA, Mutebi A, Zhou ZY, Ricculli ML, Tang W, Wang H, Guerin A, Arnhart T, Dalal A, Sasane M, Wu KY, Culver KW, Otterson GA (2019) Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. JCO Precis Oncol 3:1\u20139. https:\/\/doi.org\/10.1200\/PO.18.00356","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"5055_CR48","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/nejmoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D, Ou SI, P\u00e9rol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T (2017) Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer. New Engl J Med 377(9):829\u2013838. https:\/\/doi.org\/10.1056\/nejmoa1704795","journal-title":"New Engl J Med"},{"issue":"1","key":"5055_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10787-022-01115-7","volume":"31","author":"S Sadeghi","year":"2023","unstructured":"Sadeghi S, Tehrani FR, Tahmasebi S, Shafee A, Hashemi SM (2023) Exosome engineering in cell therapy and drug delivery. Inflammopharmacology 31(1):145\u2013169","journal-title":"Inflammopharmacology"},{"key":"5055_CR50","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.1016\/j.jtho.2020.08.003","volume":"15","author":"G Selvaggi","year":"2020","unstructured":"Selvaggi G, Wakelee HA, Mok T, Wu YL, Reck M, Chiappori A, Cicin I, Lee DH, Breder V, Fan Y (2020) ID:1882 phase III randomized study of ensartinib vs crizotinib in ALK(ALK) positive NSCLC patients: eXalt3. J Thorac Oncol 15:E41\u2013E42","journal-title":"J Thorac Oncol"},{"issue":"21","key":"5055_CR51","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ, CROWN Trial Investigators (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018\u20132029. https:\/\/doi.org\/10.1056\/NEJMoa2027187","journal-title":"N Engl J Med"},{"issue":"7","key":"5055_CR52","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Kim TM, Crin\u00f2 L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E (2017) Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18(7):874\u2013886. https:\/\/doi.org\/10.1016\/S1470-2045(17)30339-X","journal-title":"Lancet Oncol"},{"key":"5055_CR53","doi-asserted-by":"publisher","unstructured":"Shaw AT, Kim D, Nakagawa K. Seto T, Crin\u00f3 L, Ahn M, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu Y, Thomas M, O\u2019Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, . . . J\u00e4nne PA (2013) Crizotinib versus chemotherapy in advanced ALK -positive lung cancer. New Engl J Med 368(25):2385\u20132394. https:\/\/doi.org\/10.1056\/nejmoa1214886","DOI":"10.1056\/nejmoa1214886"},{"issue":"7153","key":"5055_CR54","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561\u2013566. https:\/\/doi.org\/10.1038\/nature05945","journal-title":"Nature"},{"issue":"23","key":"5055_CR55","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/nejmoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med 371(23):2167\u20132177. https:\/\/doi.org\/10.1056\/nejmoa1408440","journal-title":"New Engl J Med"},{"issue":"12","key":"5055_CR56","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou S-HI, Shaw AT (2018) Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 19(12):1654\u20131667. https:\/\/doi.org\/10.1016\/S1470-2045(18)30649-1","journal-title":"Lancet Oncol"},{"issue":"22","key":"5055_CR57","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","volume":"36","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS (2018) Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol 36(22):2251\u20132258. https:\/\/doi.org\/10.1200\/JCO.2017.77.4794","journal-title":"J Clin Oncol"},{"issue":"4","key":"5055_CR58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, L\u00f3pez FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E (2023) Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 11(4):354\u2013366. https:\/\/doi.org\/10.1016\/S2213-2600(22)00437-4","journal-title":"Lancet Respir Med"},{"key":"5055_CR59","doi-asserted-by":"publisher","unstructured":"Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, ... de Castro G Jr (2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389(10072):917\u2013929. https:\/\/doi.org\/10.1016\/S0140-6736(17)30123-X","DOI":"10.1016\/S0140-6736(17)30123-X"},{"issue":"9","key":"5055_CR60","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10(9):1240\u20131242. https:\/\/doi.org\/10.1097\/JTO.0000000000000663","journal-title":"J Thorac Oncol"},{"issue":"5","key":"5055_CR61","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jtho.2016.03.012","volume":"11","author":"AS Tsao","year":"2016","unstructured":"Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou S-H, Reungwetwattana T, J\u00e4nne PA, Mok TS, Wakelee HA, Pirker R, Mazi\u00e8res J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI (2016) Scientific advances in lung cancer 2015. J Thorac Oncol 11(5):613\u2013638. https:\/\/doi.org\/10.1016\/j.jtho.2016.03.012","journal-title":"J Thorac Oncol"},{"key":"5055_CR62","doi-asserted-by":"publisher","unstructured":"Wang Y, Yuan X, Xiong J, Hao Z, Peng X, Chen W, Cui L, Li H, Wang X, He X, Yang M, Liang C, Ma Y, Ding L, Mao L (2020) Zhongguo fei ai za zhi = Chin J Lung Cancer 23(8):719\u2013729. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2020.102.34","DOI":"10.3779\/j.issn.1009-3419.2020.102.34"},{"issue":"10","key":"5055_CR63","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","volume":"13","author":"YL Wu","year":"2018","unstructured":"Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS (2018) Results of PROFILE 1029, a phase III comparison of\u00a0first-line crizotinib versus chemotherapy in\u00a0East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol 13(10):1539\u20131548. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.012","journal-title":"J Thorac Oncol"},{"key":"5055_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216140","volume":"561","author":"Y Xia","year":"2023","unstructured":"Xia Y, Jin R, Li M, Lan F, Zhu H, Yu Y, Miao D, Wang Q, Zhou Y, Selvaggi G, Ying S, Zhang J, Shen H, Le X, Li W (2023) Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer. Cancer Lett 561:216140. https:\/\/doi.org\/10.1016\/j.canlet.2023.216140","journal-title":"Cancer Lett"},{"issue":"2","key":"5055_CR65","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1148\/radiol.14140789","volume":"272","author":"S Yamamoto","year":"2014","unstructured":"Yamamoto S, Korn RL, Oklu R, Migdal C, Gotway MB, Weiss GJ, Iafrate AJ, Kim DW, Kuo MD (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272(2):568\u2013576. https:\/\/doi.org\/10.1148\/radiol.14140789","journal-title":"Radiology"},{"issue":"1","key":"5055_CR66","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(19)30252-8","volume":"8","author":"Y Yang","year":"2020","unstructured":"Yang Y, Zhou J, Zhou J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Zhang L (2020) Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respir Med 8(1):45\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(19)30252-8","journal-title":"Lancet Respir Med"},{"issue":"6","key":"5055_CR67","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT (2018) Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov 8(6):714\u2013729. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1256","journal-title":"Cancer Discov"},{"issue":"5","key":"5055_CR68","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","volume":"7","author":"C Zhou","year":"2019","unstructured":"Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L (2019) Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med 7(5):437\u2013446. https:\/\/doi.org\/10.1016\/S2213-2600(19)30053-0","journal-title":"Lancet Respir Med"},{"issue":"1","key":"5055_CR69","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","volume":"28","author":"HY Zou","year":"2015","unstructured":"Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T (2015) PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28(1):70\u201381. https:\/\/doi.org\/10.1016\/j.ccell.2015.05.010","journal-title":"Cancer Cell"},{"issue":"20","key":"5055_CR70","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05055-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:03:41Z","timestamp":1782140621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05055-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5055"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05055-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. As this is a review article, formal ethical approval was not required as per our institution\u2019s guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}